AI-generated analysis. Always verify with the original filing.
Pyxis Oncology reported full year 2025 financial results with total revenues of $13.9 million, net loss of $79.6 million or ($1.28) per share, and cash position of $68.3 million sufficient to fund operations into Q4 2026. The company completed target enrollment in the Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC and announced leadership appointments.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 23, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results f
Regulation FD Disclosure. On March 23, 2026, the Company made available an updated corporate presentation on the Company’s website. A copy of the corporate pres
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 23, 2026 99.2 Pyxis Oncology Corporate Presentation dated
| Metric | Value | Basis |
|---|---|---|
| Total Revenues | $13.86 | |
| Research and Development Expenses | $73.70 | |
| General and Administrative Expenses | $22.19 | |
| Net Loss | $-79.62 | |
| Net Loss per Common Share - Basic and Diluted | $-1.28 |
Thomas Civik
Effective: 2026-02
Heather Knowles
Effective: 2026-01
Alex Kane
Effective: 2025-10
Brian Freeman
Effective: 2025-05